On February 28, 2025, ALX Oncology announced a 30% workforce reduction to prioritize its pipeline and save cash, incurring approximately $2.2 million in related expenses, with completion expected by May 2025. Additionally, the President and Chief Scientific Officer will depart in April 2025, receiving severance benefits as per his agreement.